Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update

GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a yearA single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPDZealand Pharma collaboration provides $30 million upfront, $35 million in early preclinical milestones and nearl…